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Lymphoma, Leg Type, May Escape Detection by Standard
FISH Assays
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TO THE EDITOR
Primary cutaneous large B-cell lympho-
ma, leg type is a neoplastic proliferation
of large, atypical B-lymphocytes, typi-
cally presenting with rapidly growing,
reddish-brown plaques and tumors on
the lower legs (Cerroni et al., 2005;
Willemze et al., 2005). The 5-year
survival rate is around 50% (Willemze
et al., 2005). The main adverse prog-
nostic factors include advanced age,
presence of multiple skin lesions, and
location on the leg (Kodama et al., 2005;
Grange et al., 2007). Recently, deletion
at chromosome region 9p21 has been
associated with a poor prognosis, pre-
dicting a 5-year survival rate of 27% as
compared to 100% in cases without
deletion (Senff et al., 2007). Among
different techniques for the identification
of the 9p21 deletion, such as multiplex
ligation-dependent probe amplification
or array-based comparative genomic
hybridization (CGH), interphase fluores-
cence in situ hybridization (FISH) em-
ploying commercially available probes
(Vysis) has evolved as standard method
(Wiesner et al., 2005; Dijkman et al.,
2006; Senff et al., 2007). The assessment
of clinical, histopathological, and mole-
cular genetic features in each patient
with primary cutaneous large B-cell
lymphoma, leg type, is crucial for
individualized management decisions,
which may range from local radiotherapy
to aggressive systemic chemotherapy.
Here we show that determination of
9p21 deletions may require more sophis-
ticated approaches than the aforemen-
Abbreviations: BAC, bacterial artificial chromosome; CGH, comparative genomic hybridization;
FISH, fluorescence in situ hybridization
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9p21 deletion in pcLBCL, leg type
tioned standard FISH assay. The study was
approved by the institutional ethical re-
view board and was conducted according
to the Declaration of Helsinki Principles,
and patient consent was obtained. An
84-year-old male patient presented with a
3-month history of reddish, rapidly grow-
ing, grouped tumors on the left lower leg
(Figure 1a). Histopathology revealed mor-
phologic and phenotypic features of large
B-cell lymphoma, leg type (Figure 1b). No
systemic involvement was found after
complete staging investigations and a
diagnosis of primary cutaneous large B-
cell lymphoma, leg type was made. FISH
did not show a 9p21 deletion (Figure 2a),
but despite the presumed good prognosis
the disease was progressive with onset of
new lesions. To define genomic aberra-
tions more precisely, we used array-based
CGH, which is a powerful technique
allowing genome-wide analysis of chro-
mosomal changes at a high resolution in a
single experiment (Zielinski et al., 2005).
In addition to other genomic changes,
array-based CGH identified, in contrast to
the standard FISH, a 100 kb sized deletion
at 9p21 (Figure 2b).
To further analyze these discrepant
results, we compared size and exact
physical location of the commercial
probe and the bacterial artificial
chromosome (BAC) clone RP11-149I2,
which was deleted according to
array-CGH. The comparison revealed
that the commercial probe actually
includes the deleted region. However,
as the commercial probe is significantly
larger than the bacterial artificial
chromosome clone, it also covers large
areas outside of the deleted region and
therefore hybridization of this probe
does not result in a detectable reduction
of the FISH signal (Figure 2a and c). We
next repeated FISH using bacterial artifi-
cial chromosome clone RP11-149I2
from the 9p21 region, which confirmed
that this region was indeed deleted
(Figure 2d).
On the basis of the progressive
clinical course and on the confirmed
9p21 deletion a systemic anthracycline-
based chemotherapy in combination
with rituximab was started, instead of
the initially performed radiotherapy.
Radiotherapy was selected as first
treatment choice, because of the pa-
tient’s advanced age and his poor
health. The skin lesions disappeared
completely under chemotherapy.
This case shows that standard FISH
analysis using commercially available
probes may not be sufficient to detect
small but prognostically important 9p21
deletions. Other region-specific ap-
proaches, such as multiplex ligation-
dependent probe amplification or tiling-
a b
Figure 1. Clinical and histological picture. (a) Reddish, grouped plaques and tumors on the left lower
leg. (b) Dense, diffuse infiltrate of large, atypical lymphocytes with predominant round cell
morphology (immunoblasts; bar¼20 mm).
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Figure 2. Molecular genetic results. (a) Interphase-FISH using the Vysis LSI p16 (9p21) probe (yellow signal) and a centromere 9 control probe (green
signal), shows two signals of each probe suggesting no 9p21 deletion. (b) Array-based CGH shows gains on chromosome 3, 7, 10, 11, 18, and 19 as well as
losses on 6, 9 and 12. The two red overlapping dots on chromosome 9 represent both the BAC clone RP11-149I2, which was printed in duplicate on our
array. The two representations of this particular BAC clone were assigned slightly different mapping information so that the results for each spot become
visible. For each spot an almost identical log2 ratio was measured demonstrating the accuracy and reproducibility of array-CGH for this region. (c) Size and
mapping of the commercial Vysis LSI p16 (9p21) probe and the clone RP11-149I2 on chromosome region 9p21. (d) FISH using the BAC clone RP11-149I2
detects the 9p21 deletion. The two green control probes confirm two chromosomes 9; one red signal indicates the 9p21 deletion.
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path arrays, may have a superior resolu-
tion and may evolve to important
alternatives to FISH. Genome-wide,
high-resolution analyses—as applied
here—yield additional information as
compared to region-specific approaches
and have therefore the potential to
identify additional genomic regions of
prognostic relevance. This case demon-
strates that all molecular genetic results
should be considered critically under
the light of the clinical picture.
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Keratinocytes Is Modulated by Cell Differentiation
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TO THE EDITOR
Recently, IL-31 has been identified as a
short-chain 4-helix bundle cytokine that
is expressed by activated CD4þ T cells,
preferentially by T cells skewed toward
a T helper type 2 TH2-type pheno-
type (Dillon et al., 2004). IL-31 signals
through a heteromeric receptor complex
composed of the IL-31 receptor alpha
(IL-31Ra) and the oncostatin M receptor
beta (Dillon et al., 2004). The IL-31Ra
was originally identified as gp130-like
monocyte receptor (Ghilardi et al.,
2002) and gp130-like receptor (Diveu
et al., 2003, Dreuw et al., 2004) and
shows 28% homology to gp130, the
common signaling receptor subunit of
the family of IL-6-type cytokines.
Expressions of IL-31Ra and oncosta-
tin M receptor beta mRNA have been
shown to be induced in activated
monocytes, whereas tissues of the skin,
testis, thymus, and trachea, as well as
intestinal epithelial cells and dorsal
root ganglia express mRNA for both
receptors constitutively (Dillon et al.,
2004; Bando et al., 2006; Sonkoly
et al., 2006; Dambacher et al., 2007).
Engagement of the receptor complex
resulted in activation of Jak1, and to a
minor extent of Jak2, as well as STAT1,
STAT3, STAT5, and MAPK and PI3K
signaling pathways in glioblastoma and
melanoma tumor cells and lung epithe-
lial cells (Diveu et al., 2004; Chatto-
padhyay et al., 2007, Dambacher et al.,
2007).
So far, biological functions of this
previously unknown cytokine were
mainly analyzed in skin diseases such
as atopic dermatitis (AD) or allergic
contact dermatitis, in which increased
expression rates of IL-31 were detected
(Neis et al., 2006, Bilsborough et al.,
2006, Sonkoly et al., 2006). In vivo,
Staphylococcal superantigen strongly
induced IL-31 expression in PBMCs
obtained from patients with AD (Sonkoly
et al., 2006). In psoriatic plaques, ex-
pression of IL-31 was absent, confirming
an involvement of IL-31 in TH2-
Abbreviations: AD, atopic dermatitis; IL-31Ra, IL-31 receptor alpha; NHEK, normal human epidermal
keratinocyte; TH2, T helper type 2
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